Formation of metastases, also known as cancer dissemination, is an important stage of breast cancer (BrCa) development. KISS1 expression is associated with inhibition of metastases development. Recently we have demonstrated that BrCa metastases to the brain exhibit low levels of KISS1 expression at both mRNA and protein levels. By using multicolor immunofluorescence and coculture techniques here we show that normal adult astrocytes in the brain are capable of promoting metastatic transformation of circulating breast cancer cells localized to the brain through secretion of chemokine CXCL12. The latter was found in this study to downregulate KISS1 expression at the post-transcriptional level via induction of microRNA-345 (MIR345). Furthermore, we demonstrated that ectopic expression of KISS1 downregulates ATG5 and ATG7, 2 key modulators of autophagy, and works concurrently with autophagy inhibitors, thereby implicating autophagy in the mechanism of KISS1-mediated BrCa metastatic transformation. We also found that expression of KISS1 in human breast tumor specimens inversely correlates with that of MMP9 and IL8, implicated in the mechanism of metastatic invasion, thereby supporting the role of KISS1 as a potential regulator of BrCa metastatic invasion in the brain. This conclusion is further supported by the ability of KISS1, ectopically overexpressed from an adenoviral vector in MDA-MB-231Br cells with silenced expression of the endogenous gene, to revert invasive phenotype of those cells. Taken together, our results strongly suggest that human adult astrocytes can promote brain invasion of the brain-localized circulating breast cancer cells by upregulating autophagy signaling pathways via the CXCL12-MIR345-KISS1 axis.
Introduction
Breast cancer (BrCa) is the most common primary malignancy of women, accounting for almost 30% of all female cancers worldwide. Breast cancer mortality is associated with the dissemination of cancer cells to multiple organs such as lungs, bones and brain. 1 The mechanism of BrCa dissemination is complex and involves several genes, 2 some of which serve as mediators, while others as suppressors 3 of metastasis. Among the suppressors, the KISS1/kisspeptin 1 (KiSS-1 metastasis-suppressor) gene deserves special attention. This gene encodes a 145-amino acid (aa) precursor peptide that becomes cleaved into several short peptides of 10 4 -, 13-and 14 aa in length. KISS1 inhibits growth and invasion of osteosarcoma 5 and prostate cancer cells. 6 Whereas deficiency of KISS1 expression in tumor tissues is associated with cancer progression, 7 overexpression of this protein can suppresses the formation of metastases 8 via molecular mechanisms involving KISS1R 9 and CXCR4 10 receptors. Although, our group 11 and others 12 have found a significant reduction in KISS1 expression in BrCa metastases to the brain relative to primary BrCa tumors, the precise role of KISS1 in the development and progression of brain metastases remains unknown. The objective of this study was to investigate the role of KISS1 in modulating brain metastases and to reveal the upstream and the downstream effectors of KISS1 downregulation.
Development of brain metastases is a result of complex interplay between the tumor cells and the tumor environment, 13 which is represented predominantly by normal astrocytes in the brain tissue. Astrocytes regulate the brain response to inflammation, 14 maintain brain homeostasis 15 and provide protection of neurons from hypoxia. 16 Conversely, reactive astrocytes can play a mitogenic role by secreting interleukins and chemokines, such as CCL2 and CXCL12/SDF1, respectively. The latter can serve as a chemoattractant for highly metastatic CXCR4 C cells. 17 Elevated levels of CCL2 and CXCL12 expression have also been linked to tumor progression and development of metastases. 18 Although normal astrocytes have been linked with tumor progression, 14 the role of these cells in brain metastases is still unclear. Here we provide the first evidence that normal astrocytes can promote brain metastases through downregulation of KISS1 and activation of the autophagy survival pathway in circulating BrCa cells.
Results

Primary tumors release KISS1-expressing cancer stem cells into the bloodstream
BrCa is represented by highly heterogeneous tumor types, 19 each containing a distinctive population of cancer cells with stem cell properties, 20 resistance to conventional BrCa therapies, 21 and capability of migrating 22 and initiating metastases in the brain. We hypothesized that blood-circulating cancer stem cells (CSC) with a self-renewal property and a KISS1-deficient phenotype could give rise to metastatic foci in the brain. To identify and isolate a population of circulating tumor cells (CTCs), we used a previously described 23 MDA-MB-231 metastatic model of human BrCa in mice. 24 We observed a strong association between primary tumor growth and number of CTCs in the blood (Fig. S1A to D) . Using an in vitro tumorigenicity analysis we showed that CD24 ¡/LOW and CD44 C cells exhibit a »7.2-and »1.48-fold higher potential to form tumors as compared with CD24
C and CD44 C or parental cells, respectively ( Fig. S1E , P < 0.05), which highlights their potential for forming secondary tumors. In addition, flow cytometry together with the ALDEFLUOR assay 25 ( Fig. S1F ) demonstrate that the CD24 ¡/LOW and CD44 C population of CSCs isolated from blood (CTC) is metabolically active. We also observed that the CD24 ¡ and CD44 C population of CTCs isolated from nude mice with established MDA-MB-231 mammary tumor xenografts exhibits a 4.7-fold higher expression of KISS1 mRNA (Fig. S1G ), compared with parental CSCs (P < 0.05). There was, however, no correlation between the KISS1 mRNA levels and those of the ST6GALNAC6 gene, 26 implicated in priming BrCa cells to the brain (Fig. S1H) .
Cancer stem cells, identified in BrCa brain metastases by CD44, CD24 and FLOT2 markers, express low level of KISS1 Our next step was to characterize expression of KISS1 in a small subset of metastatic cells called cancer stem cells (CSCs), identified by expression of stem cell markers CD44 and CD24 27 in the primary brain metastatic tissue. Given the low expression levels of KISS1 in BrCa brain metastases, 11 we hypothesized that high expression of KISS1 in CTCs entering the brain could be locally modulated by the brain tissue environment. As evident from Fig. 1A , RONC1 and RONC-BM35 tumor specimens are composed of either distinct CD24-or CD44-positive cells, since no overlap in cell populations expressing those surface markers was observed. Therefore, we characterized CD44 C CSC populations expressing FLOT2/ESA1 28 and KISS1. At the onset, we identified a CD44
C , FLOT2 C and KISS1 ¡ CSC population that exhibited colocalization of only 2 distinct IF signals (red and green, respectively), resulting in sky blue cell staining, and subsequently looked for subpopulations also positive for KISS1 expression (CD44 C , FLOT2 C and KISS1 C ) by triple IF staining. These experiments revealed cells with "white" colocalization signal (Fig. 1B,C) . While the stem cell population in the primary tumors comprised KISS1-positive (KISS1 C ) subtypes (average 0.95 § 0.44 per high power field, Fig. 1D ), brain metastatic lesions contained mostly KISS1-negative stem cells (average 1.8 § 0.85 per high power field, Fig. 1D ) These data are consistent with our earlier finding that brain metastatic lesions exhibit drastically lower KISS1 expression levels relative to primary BrCa tumors. 11 Normal human astrocytes downregulate KISS1 in brain metastases via production of CCL2 and CXCL12
At the next step we determined the region in brain that can modulate KISS1 expression. Given the fact that astrocytes are capable of modulating biologic properties and behavior of cancer cells, 12 we hypothesized that they could induce formation of brain metastases through suppression of KISS1 expression among BrCa cells, entering into the brain. For instance, a triple IF staining of brain metastatic specimens for an astrocyte-specific marker GFAP, a stem cell marker, and CD44 and KISS1 showed that CD44
C and KISS1 C BrCa cells tend to lose KISS1 expression (red in Fig. 2A ) after coming into direct contact with GFAP-positive astrocytes (green in Fig. 2A ). To find out if human adult astrocytes are capable of modulating KISS1 expression in BrCa CTCs, we examined the level of KISS1 expression in GFP-tagged cancer cells (CN34-GFP, CN34Br-GFP, MDA-MB-231Br-GFP and 4T1Br-GFP) by coculturing them with normal human astrocytes (NHA) or human microglia (HM) in vitro (Fig. 2B, C) . Although we observed that only parental CN34 BrCa cells upon their coculturing with astrocytes or human microglia induce KISS1 mRNA (P < 0.05), the brain-primed metastatic MDA-MB-231Br, CN34Br or 4T1Br cancer cells exhibited greater level of KISS1 downregulation (»65%, »82% and »52% reduction vs Mock, respectively) as a result of direct contact with astrocytes. This effect was mediated by a 10-to 1000-fold increase in CXCL1 (P D 0.02), CCL2 (P D 0.015) and CXCL12 (P D 0.023) mRNA expression levels in astrocytes (Fig. 2D ) induced through contact with the cancer cells. Furthermore, we discovered that KISS1 expression in CN34Br cells gets selectively inhibited by human CXCL12 and CCL2 proteins in a dose-dependent manner ( Fig. 2E , P < 0.05), which was further confirmed by IF staining (data not shown). While no colocalization was observed for CCL2 and astrocyte-specific GFAP staining (Fig. 2F, left panels) , a distinctive colocalization (yellow and orange signal on merged images) was observed for CXCL12 and GFAP markers in brain metastatic tissues (Fig. 2F, right panels) , highlighting the clinical significance of CXCL12
C and GFAP C reactive astrocytes for the survival of patients with BrCa brain metastases after surgery (Fig. 2G) . As expected, the presence of CXCL12
¡ and GFAP 
KISS1 mRNA is a direct target for MIR345
It remains unclear how the CXCL12 chemokine, released by astrocytes, modulates KISS1 expression. Since treatment of BrCa cells with CXCL12 has been shown to induce expression of cellular microRNAs, 29 and suppression of CXCL12 has been found to reduce cancer cell metastases, 30 we hypothesized that CXCL12 could induce a KISS1-targeting microRNA, silencing expression of KISS1 mRNA in metastatic BrCa cells (Fig. S2 ). In line with the above possibility, some experimental data (Ulasov et al., unpublished) indicated to MIR345 and MIR146B as best candidates for the role of post-transcriptional regulators of KISS1 expression, since their induction inversely correlated with KISS1 expression levels in primary tumors, based on quantitative PCR analyses of cancer patient samples. Conversely, among 5 candidate miRNAs with predicted ability to bind (base pair to) the 3 0 UTR of the human KISS1 mRNA (TargetScan-based computational analysis), MIR345 and MIR146B were the only ones whose expression in CN34Br and MDA-MB-231Br brain metastatic cells increased in response to treatment with CXCL12 or CCL2 proteins (Fig. 3A) . Indeed, CXCL12 was experimentally confirmed to induce the expression of MIR345 in a dose-dependent manner, whereas Gene Ontology analysis indicated that MIR345 could potentially modulate a cytokine-mediated signaling pathway ( Fig. 3B , P D 0.0007, FDR<2%). Thus regulation of KISS1 expression at post-transcriptional level in response to CXCL12 or CCL2 was assumed and further directly validated by in vitro assays, using cancer cells stably expressing GFP or Luciferase (Luc) reporters, fused to the 3 0 UTR sequence (bearing potential MIR345 target site) of the human KISS1 mRNA. Expression of the reporters was analyzed following treatment of the transfected cells with NHA-conditioned media or individual recombinant CCL2 or CXCL12 proteins (Fig. S3) . Alternatively, the reporter gene expression was analyzed following a direct transfection of the cells with human MIR345-5p mimic. As expected, treatment with either purified CXCL12 (P D 0.003) or MIR345-5p mimic (P D 0.018) significantly decreased expression of GFP from the 
GFP-KISS1-3
0 UTR (Fig. 3C,D ,F,G and S3) reporter construct (at 1 ng/ml) in CN34Br cells. A similar inhibitory effect was observed upon treatment of CN34Br cells with astrocyte-conditioned media (P D 0.038), which could be reversed by addition of AMD3100 (P D 0.007 relative to NHA-conditioned media treatment), a chemical inhibitor of CXCR4 signaling (Fig. 3E,  H) , strongly supporting involvement of CXCR4 in the mechanism of KISS1 downregulation. Conversely, transfection of MDA-MB-231Br cells with MIR345-5p mimic inhibited expression of KISS1 mRNA ( Fig. 4A , P D 0.038) or Luc-KISS1-3 0 UTR (Fig. 4B ) reporter fusions by 50 to 60% relative to untargeted ("nontargeting") control miRNA (P D 0.016). On the contrary, no change in Luc expression was observed for a MUT 3 0 UTR construct bearing a mutation in the MIR345 binding side within the KISS1 mRNA 3 0 UTR sequence (Fig. S4) . Finally, our data suggest that the expression of MIR345 in tumors Total RNA was isolated as described in Materials and Methods, converted to cDNA and KISS1 mRNA expression was quantified by RT-qPCR using the DDCt method. Results were plotted after normalization to ACTB and presented as KISS1 mRNA expression. Experiment was performed twice in triplicate. Red bars, KISS1 mRNA in mock-treated control cells; blue bars, KISS1 mRNA in cancer cells cocultured with human astrocytes; black bars, KISS1 mRNA expression in the presence of human microglia; P values were determined using a Student t test; P < 0.05 indicates a significant difference in KISS1 mRNA expression relative to mock-treated control cells. (C) RT-qPCR analysis of KISS1 mRNA expression in GFP-labeled MDA-MB-231Br or 4T1Br metastatic BrCa cells after their coculturing with normal astrocytes (human or mouse, normal astrocytes (NA) coculture) or culturing in the presence of astrocyte conditioned medium (NA cond. medium) plotted as a bar graph. The experiment reveals downregulation of KISS1 expression upon contact with astrocytes or astrocyte-conditioned medium. Red bars, expression in mock treated cells; blue bars, expression following coculturing with astrocytes; green bars, expression resulting from incubation in astrocyte-conditioned medium. Experiment was performed twice in triplicate; Ã P < 0.05 relative to mocktreated cells determined by the Student t test indicates statistical significance. (D) GFP-negative population of astrocytes cocultured with CN34Br cells were isolated by flow cytometry and total RNA was analyzed by real-time PCR to determine expression of various chemokines. Quantitative PCR for relative expression of the most regulated human chemokines CCL2, CCL3, CCL8, CXCL12 and CXCL1 was performed using cDNA from astrocytes cultured with (blue bars) or without (mock/red bars) CN34Br metastatic BrCa cells and presented as chemokine mRNA expression per housekeeping b-actin/ACTB mRNA (normalization control). Experiment was performed twice with 5 replicates per sample; P < 0.05 indicates statistical significance of changes assessed by a Student t test. (E) Treatment of CN34Br metastatic BrCa cells with recombinant CCL2 or CXCL12 proteins decreases KISS1 mRNA levels as revealed by RT-qPCR analysis. Expression of KISS1 mRNA in the presence of 1 (red bars), 10 (blue bars) or 50 (white bars) ng/ml of human CCL2, CXCL12, CXCL1 or CCL8 chemokines was analyzed and presented as KISS1 mRNA copy number per ACTB; P < 0.05 indicate statistically significant differences determined by a Student t test. (F) Immunofluorescent detection of CCL2 or CXCL12 expression in GFAP-positive astrocytes. Paraffin-embedded brain metastatic tissue specimens were stained with GFAP (green signal), CXCL12/SDF1 or CCL2 (red signal) antibodies as described in Materials and Methods. Cells were counter-stained with DAPI for nuclei (blue). . Quantitative analysis of GFP expression was performed using fluorescent images acquired by using a Nikon camera and ImageJ software; signal intensity from the region of interest (ROI) was quantified using an ROI manager. Data presented as an average ROI for each fluorescence image and sample; closed diamonds, mock-treated control cells; squares, CCL2-treated cells; closed triangles, CXCL12-treated cells; P values for changes vs mock-treated cells were calculated using the Student t test (F). (D and G) Puromycinresistant CN34Br cells stably expressing a GFP-KISS1¡3 0 UTR fusion reporter were transfected with the miRIDIAN precursor of human "mimic miRNA" MIR345-5p or a nontargeting miRNA as a negative control using a DharmaFECT1 transfection reagent; Nontransfected control cells were used as a (mock) control. Image magnification is 200X; scale bar: 50 mm (D). Quantitative analysis of GFP reporter expression was performed using fluorescent images collected 48 h post transfection, and analyzed (8 images per sample) by ImageJ after subtracting the background; other details as in (C). Closed diamonds, mock-treated cells; closed squares, nontargeting miRNA (Nc miRNA); closed triangles, MIR345-5p; P value of 0.018 relates to differences versus cells treated with nontargeting miRNA calculated using the Student t test (G). ((E)and H) Treatment of puromycin-resistant CB34Br cells stably expressing a GFP-KISS1 3 0 UTR fusion reporter with conditioned media from normal human astrocytes (NHA) demonstrates silencing of GFP expression in vitro. However, this silencing effect is attenuated in the presence of the CXCR4 inhibitor AMD3100. Images of BrCa cells were acquired after 48 h of incubation in the presence of astrocyte conditioned media § AMD3100; image magnification is 200X, scale bar is 50 mm (E); Quantification details are as in G; closed squares-mock treated CB34Br cells; closed triangles-cells treated with NHA conditioned media; closed inverted triangles-cells pretreated with AMD3100 and incubated with NHA-conditioned media (H).
inversely correlates with the KISS1 mRNA levels, whereas low expression of this miRNA is associated with longer survival of the patients with brain metastases (Fig. 4C,D) . Altogether, our findings suggest that in CSC downregulation of KISS1 expression occurs on a post-transcriptional (mRNA) level through expression of cellular MIR345 modulated by the NHA-released chemokine CXCL12.
KISS1 inhibition promotes autophagy
Although BrCa cells can easily migrate to the brain, their survival in the brain tissue environment becomes a serious challenge. Because BCL2 expression is known 31, 32 to be associated with cell survival and promoted by autophagy as well as antiapoptotic mechanisms, and since our data presented in Fig. 1 suggest a correlation between survival of tumor stem cells and their KISS1 deficiency, we stained primary specimens with BCL2-and KISS1-specific antibodies. We found a large population of brain-localized metastatic BrCa cells with upregulated BCL2, a marker of apoptotic resistance and autophagy survival (Fig. 5A,B ), that were deficient in KISS1 expression. This finding suggests that KISS1 could be involved in the mechanism of cancer cell survival in the brain. To find out if KISS1 expression prevents metastatic cell survival in the brain, we ectopically overexpressed KISS1 in metastatic BrCa cells (Fig. S5) . We observed that overexpression of KISS1 reduces ATG5 and ATG7 and inhibits conversion of LC3-I to LC3-II (Fig. 5C,D) , which links KISS1 overexpression to autophagy inhibition. On the contrary, downregulation of KISS1 with the KISS1-KD61 shRNA construct reduces cellular accumulation of SQSTM1/ p62 (1.47-fold). It has been shown that inhibition of SQSTM1 causes autophagic cell death in several human carcinoma cells. 33 Our data suggests that SQSTM1 downregulation is accompanied by upregulation of ATG5 (1.5-fold), ATG7 (1.4-fold) and conversion of LC3-I to LC3-II (autophagy markers), (Fig. 5E to H) in brain metastatic cells. This observation suggests that KISS1 expression can directly modulate autophagy. Besides, siRNA-mediated silencing of Kiss1 improved the survival of 4T1Br BrCa cells (Fig. S6A ) by suppressing apoptosis (Fig. S6C ). In addition, KISS1 overexpression increased apoptosis (Fig. S6D) . Furthermore, KISS1 knockdown resulted in the upregulation of BECN1/Beclin 1 mRNA (Fig. S7 ) and downregulation of SQSTM1 (Fig. 6A,B) . Consistently with our observations, ectopic expression of KISS1 reduced ATG5 and ATG7 expression, while increasing accumulation of SQSTM1 (Fig. 6A) . On the other hand, 3-methyladenine (3-Ma) inhibitor significantly suppressed autophagy in KISS1-KD61 (4-fold vs DMSO-treated) and control scrambled shRNA (1.6-fold vs DMSO-treated) MDA-MB-231Br-based cells, while pretreatment with bafilomycin A 1 (BafA1, an inhibitor of autophagososme maturation) promoted autophagy (»2.2-fold) as revealed by the increase in SQSTM1 expression in KISS1-KD61 cells vs shScrambled control cells (Fig. 6B) . Finally, expression of KISS1 from an adenoviral vector in MDA-MB-231Br cells exerted a synergistic effect with 3-Ma treatment by suppressing autophagy and promoting SQSTM1 expression (4.92-fold). Conversely, an ectopic expression of KISS1 (Fig. 6C ) suppressed autophagy in MDA-MB-231Br cells, upregulated SQSTM1 (2.5-fold) and exhibited low level of LC3-II (1.75-vs 1.38-fold) in the presence of BafA1 in Ad-infected cells (empty vector control). Such correlation between KISS1 and SQSTM1 expression on both mRNA (Fig. 6E , P D 0.015) and protein (Fig. 6D,F ) levels was also observed in human brain metastatic specimens (immunohistochemical [IHC] staining, Fig. 6D ) and intracranial metastases of MDA-MB-231Br cells (yellow immunofluorescence signal (Fig. 6F) , using intracranial route of tumor cells implantation, suggesting that downregulation of KISS1 in metastatic BrCa lesions in the brain leads to activation of autophagy.
Since coculturing of BrCa cells with NHA activates autophagy via KISS1 downregulation in BrCa cells, we sought to determine if this activation could improve anticancer properties of autophagy-dependent drugs such as temozolomide (TMZ) used to improve the efficacy of radiation therapy. Of note, combination of those approaches requires induction of autophagy. 34 In line with this suggestion, activation of autophagy via KISS1 silencing increased antiproliferative activity of TMZ (20% to 65% depending on TMZ concentration) (Fig. 7A,B) . Furthermore, prior treatment of KISS1-KD79 knockdown MDA-MB-231Br cells with an autophagy inhibitor 3-Ma, reduced TMZ-associated cytotoxicity 2-fold (P < 0.05) (Fig. 7C,D) . These findings underline the important role of KISS1 in the mechanism of metastatic brain tumor sensitivity to cytotoxic agents and suggest high therapeutic potential of autophagy-modulating agents for the treatment of brain metastases.
Downregulation of KISS1 in BrCa cells promotes their metastatic invasiveness into the brain
To understand the role of KISS1 protein in the fate of BrCa cells disseminated in the brain we assessed the metastatic potential of KISS1-deficient cells. Since astrocytes can produce mediators of metastases, we hypothesized that expression of CXCL12 could induce metastatic activity in CN34Br and MDA-MB-231Br cells. Previously KISS1 was reported to suppress invasion and migration of both normal 6, 35 and cancerous 36,37 cells. Interestingly, KISS1 expression has previously been reported to inversely correlate with that of MMP9, 38, 39 known to promote invasion 40, 41 and migration 42 of BrCa cells. As shown in Fig. 8A to D, KISS1-deficient cell lines KISS1-KD61, KISS1-KD79 (MDA231Br-based) and Kiss1-KDA (4T1Br-based) exhibit a 2-to 3-fold increased migration toward media enriched with SDF-1a chemokine and 2-to 100-fold increase in invasiveness (Fig. S8) . Whereas inhibition of autophagy, using RNA interference against human ATG5 (Fig. 8E,F and Fig. S9 ), decreased invasiveness from 163.8 § 13.8 to 47.4 § 11.4 cells (BrCa 71% reduction, P < 0.0001), ectopic expression of KISS1 (Fig. 8G,H ) in KISS1-deficient cells repressed autophagy-mediated invasion from 65.4 § 9.21 to 47.6 § 13.1 (»27% reduction, P D 0.017) cells. Additionally, knockdown of KISS1 mRNA by shRNA silencing induced expression of MMP9, which inversely correlated with that of KISS1 in patient tumor specimens 43 as revealed by their IHC staining (the Fisher exact test, P < 0.001) (Fig. 9A) . This was consistent with our earlier findings that MMP9 expression directly correlates with metastatic progression of BrCa.
Recently, Cheng et al., and earlier Milovanovic et al., have found a direct correlation between MMP9 and IL8 expression levels and tumor progression in nasopharyngeal carcinoma 44 and BrCa patients, 45 respectively. Since expression of MMP9 inversely correlates with expression of KISS1 and directly with that of IL8, 46 we reasoned that expression of KISS1 could negatively affect IL8 expression. Indeed our antibody array data presented in Fig. S10 demonstrates that downregulation of KISS1 is associated with upregulation of IL8, which, in turn, could contribute to tumor invasion and metastatic progression. Furthermore, immunofluorescence analysis of brain tumor specimens (Fig. 9B ) confirms our in vitro finding that KISS1-specific staining does not colocalize with that for IL8, whose induction is linked to cancer metastatic progression possibly via yet another mechanism.
Discussion
Although normal adult astrocytes are critical for maintaining brain homeostasis, recent data suggest that they also play an important role in establishing brain metastases in patients with advanced form of BrCa.
14 The results of our study suggest a new mechanism for the early stage of BrCa metastases in the brain that involves a tumor suppressor factor termed KiSS-1 metastasis-suppressor (KISS1). According to the proposed mechanism, regulation of KISS1 expression, critical for realization of metastatic potential of circulating BrCa cells entering the brain, occurs on post-transcriptional level and involves cellular MIR345. The latter is induced in BrCa cells in response to chemokine CXCL12 produced in the brain environment by normal adult astrocytes. Our study provides the first evidence that a population of circulating BrCa stem cells crossing the blood brain barrier and entering the brain induces and activates expression of chemokines in NHA, which in turn mediate ; expression of SQSTM1 and KISS1 was visualized using brown dye DAB, conjugated to secondary antibody with background staining with blue dye haematoxylin or using an avidin-biotin conjugation system (F). A direct correlation between expression of SQSTM1 and KISS1 was also validated by RT-qPCR analysis of the corresponding gene's mRNA expression (E) as well as IF staining of murine intracranial MDA-MB-231Br xenografts (MDA231Br ic, (F) counterstained with DAPI using human KISS1-and SQSTM1-specific antibodies. White arrows indicate BrCa cells with detectable KISS1 (red signal) expression that in most cells colocalizes with SQSTM1 (green signal) producing orange foci (white arrows) on the merged (400X) image; scale bar: 20 mm. Spearman correlation test between KISS1 and SQSTM1 mRNA expression was used to analyze the mRNA expression results (E) (r D 0.99, P D 0.015).
downregulation of KISS1 expression in those BrCa cancer stem cells following their localization to the brain. A direct interaction with the astrocytes promotes invasion of the cancer cells into the brain parenchyma. We showed that a 24-h incubation of astrocytes (NHA) in the presence of BrCa cells is sufficient for the induction and release of CXCL12 and CCL2 by those astrocytes. The results of our experiments are consistent with high levels of CCL2 47 and CXCL12 expression found in patients with advanced stage (metastatic) BrCa. 48 We cannot rule out the possibility of autocrine regulation of CCL2 or CXCL12 (splicing variants such as CXCL12a, CXCL12b or CXCL12g) expression in astrocytes, especially given the fact that CXCL12a serves as chemoattractant for the recruitment of immune cells, such as T cells and monocytes. 49, 50 Although, expression of chemokines, such as CCL2 and CXCL12, in normal brain is low, it can be stimulated in astrocytes by various factors. 51 Our hypothesis is that astrocytes together with monocytes can contribute to brain metastases by secreting CCL2 and CXCL12. A most recent study by Lee et al. suggests that inhibition of CXCR4-CXCL12 signaling suppresses migration of circulating cancer cells through brain endothelium. 52 The astrocyte-CN34Br model is unique in that it recapitulates interaction between astrocytes and cancer cells critical for the onset of brain metastatic disease. Our data also suggest that the release of CCL2 and CXCL12 by astrocytes facilitates the survival of the cancer cells in the brain. It is, however, not clear how secretion of CCL2 and CXCL12 by astrocytes can also contribute to inflammation as one of the hallmarks of cancer progression. The latter cannot be ruled out because expression of inflammatory chemokines is known to promote metastases. Sensitivity of astrocytes to various stresses is consistent with the induction of chemokines, such as CCL2, by chemotherapeutics. 53, 54 Our study suggests that downregulation of tumor suppressor KISS1 could activate expression of proinvasive factors MMP9 and IL8. We did not aim to investigate the precise mechanism of MMP9 and/or IL8 upregulation, but our unpublished data suggest that KISS1 silencing can activate expression of transcription factors TFAP2A/AP-2a, SP1/SP-1 and induce phosphorylation of inhibitory NFKBIA/IkBa protein, essential for activation of NFKB1/NF-kB. On this basis, we speculate that activation of downstream targets, such as IL8, can occur via binding of transcription factors to the correspondent promoters and/or binding of the NFKB1/NF-kB-RELA/p50-p65 heterodimer complex to the promoter elements of downstream genes. The results of our study also suggest that induction of chemokines by astrocytes leads to upregulation of cellular microRNAs capable of modulating metastatic potential of cancer cells via downregulating KISS1 expression. We discovered that MIR345 and MIR146B are important effectors of cancer cell metastatic transformation since they can regulate KISS1. Besides KISS1, MIR345 and MIR146B regulate as many as 400 different targets involved in angiogenesis, cell adhesion etc., some of which also prevent metastatic progression of cancers. Therefore, future data mining analyses will be performed to examine the mechanism regulating expression of MIR345 and its other potential targets as well as their possible relationship. Interestingly, our findings are consistent with recent data suggesting that CXCL12 activates expression of prometastatic microRNAs. 29 Our data suggest that CXCL12 and CCL2 are important effectors of metastatic development of BrCa.
Because cancer cell survival is one of the key conditions for the development of metastases, we addressed the importance of KISS1 expression for the survival of metastatic cancer cells. We found that knockdown of KISS1 exerts a stimulating effect on expression of ATG5, implicated in autophagosome maturation. Although in our experiments ATG5 gene silencing by an RNA interference mechanism was validated independently with 3 different ATG5-specific probes at both western blot and real-time qPCR levels and found to interfere specifically with autophagyrelated cellular signaling, we cannot entirely rule out off-target effects mediated by siRNA partial complementarity to mRNAs of other genes. 55, 56 In our experiments, we observed no changes in GAPDH or ACTB mRNA expression in the presence of siRNAs against human ATG5 gene suggesting specificity of ATG5 mRNA downregulation. Previously, using a hepatocellular carcinoma model, inhibition of autophagy was found to suppress tumor growth and improve cytotoxicity mediated by cisplatin. 57 Taken together, our data demonstrate that adult astrocytes mediate suppression of KISS1 expression via the CXCL12-MIR345 paracrine loop that can promote BrCa cell invasiveness and survival in the brain. We also show for the first time that KISS1 knockdown affects downstream targets determining cancer cell survival and resistance to chemotherapy. Further studies are needed to identify therapeutic strategies for targeting KISS1-negative population of metastatic cancer cells in the brain, which could potentially improve survival of patients with advanced BrCa disease.
Materials and methods
Cells
Metastatic BrCa clones "brain seeking clones" of CN34Brm2Ctgl (CN34Br), GFP and nonlabeled MDA-MB-231Br, and parental cells CN34TGL (CN34) were obtained from Dr. Patricia Steeg (Center for Cancer Research, NIH, Bethesda, MD) and Dr. Joan Massague (Sloan-Kettering Institute, NY) in compliance with the institutional material transfer agreements. MDA-MB-231 cells were originally purchased from ATCC (HTB-26). BrCa tumor circulating cells MDA-MB-231Cherry and MDA-MB-231GFP (MDA231BrGFP) were obtained from Dr. Dmitry Malin (UWEndocrinology) and Jennifer Koblinsky (VCU), respectively. The MDA-MB-231-and CN34-based cells were cultured in the media described elsewhere. 26, 58 Briefly, MDA-MB-231Br cells were cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals, S11195H) and 100 U/ml penicillin/streptomycin; CN34 cells were cultured in M199 medium supplemented with 2.5% FBS, 10 mg/ml insulin (SigmaAldrich, I9278), 20 ng/ml EGF (Sigma-Aldrich, 324831), 100 ng/ ml cholera toxin (Sigma-Aldrich, C8052), 0.5 mg/ml hydrocortisone (Fisher Scientific, NC9881403) and 100 U/ml penicillin/ streptomycin.
Primary adult human (1800) and mouse (M1800) astrocytes and microglia (1907) were obtained from ScienCell and cultured in the media suggested by the vendor. Complete conditioned media was obtained by culturing of primary astrocytes in media from ScienCell for 6 d without change of media.
Human brain and BrCa specimens
The protocol for the use of primary specimens in the current study was approved by the Russian Oncology Center, Moscow, Russia IRB committee. A pilot tissue microarray from 10 patients with brain metastatic disease, matched and unmatched primary BrCa specimens of BrCa and 5 control patients was created (Table 1) . Primary BrCa tissue samples are: RONC1, RONC2, RONC4 and RONC10. The brain metastatic BrCa specimens are: RONC-BM, RONC-BM1, RONC-BM2, RONC-BM21, RONC-BM23, RONC-BM35, RONC-BM41, RONC-BM43, RONC-BM61 and RONC-BM321. Additionally, a tissue microarray containing BrCa from US Biomax (BR1008) was used for immunofluorescence and immunohistochemistry.
Mouse specimens
Mouse xenografts of human MDA-MB-231Br (MDA231Br) cells were obtained from an earlier study. 23 Drugs and proteins AMD3100 chemical inhibitor (A5602) and 3-Ma autophagy inhibitor (M9281) were purchased from Sigma-Aldrich, Bafilomycin A 1 (BafA1, 196000) was obtained from Calbiochem-EMD Millipore and temozolomide (T1849) was obtained from LKT.
Human recombinant CCL2 (MCP-1, 300-04), CCL8 (MCP-2, 300-15), CXCL1 (GRO-a/MGSA; 300-11), CXCL12 (SDF1a; AF-300-28A) proteins were purchased from Peprotech.
siRNA and shRNA constructs shRNA plasmids targeting the human ATG5 gene (Origene, TG314610; shATG5 versions A, B, C and D) and "scrambled" negative control (nontargeting shRNA cassette in pGFP-V-RS vector plasmid TR30013, Origene) were transfected into MDA-MB-231Br using DharmaFECT1 transfection reagent (GE Dharmacon, T-2001-01). Selection of stably-transfected clones was performed using puromycin (Invivogen, ant-pr-1) selection at 6 mg/mL antibiotic concentration. A mixture of 3 siRNA duplexes against mouse Atg5 (sc-41446) or Kiss1 genes (versions Kiss1-KDA [SR402044A], Kiss1-KDB [SR402044B] and Kiss1-KDC [SR402044C]), and scrambled negative control siRNA duplex (SR30004), purchased from Santa Cruz Biotechnology and Origene, were transiently transfected into 4T1Br cells.
Viral vectors
Lentiviruses, expressing the 3 0 UTR of the human KISS1 gene, shRNAs against human KISS1 (KISS1-KD61 and KISS1-KD79), or scrambled control shRNA (shScrambled) were obtained from ABM Inc.).
Recombinant adenovirus construction. The genome of the conditionally replicative adenovirus with mCherry red fluorescent protein on the capsid was constructed by 2-step homologous recombination (HR) in E. coli (BJ5183 strain) using a described previously E3/fiber-modified Ad5 backbone vector Ad5DE1/DE3, F5/3 59 and a modified E1 shuttle vector, pSlD24-pIX-mCherry. The E1 shuttle vector contained a fluorescent reporter mCherry coding sequence, 60 inserted downstream of the Ad5 minor capsid protein IX (pIX) gene via a linker sequence, encoding a 10-amino acid peptide (SADYKDDDDK) with an octapeptide flag motif (in bold). The flag was followed by NheI restriction site used for mCherry coding sequence (CDS) insertion to generate a pIX-Flag-mCherry fusion with expression controlled by the native pIX promoter. The shuttle also harbored a 24-base pair deletion in the Ad5 E1A gene coding sequence ("D24 0 ), as described previously, to render Ad5 Abbreviations:
Ã Status as of 11/11/2015; BrCa -breast cancer; IDC grade -the grade of invasive ductal carcinoma (IDC) in patients when diagnosed with brain metastases; TNM-breast cancer staging based on tumor size, cancer spreading to lymph nodes and metastasis occurrence; ER, PR and HER2-status of estrogen, progesterone and HER2 receptors in tissue specimens detected by immunohistochemistry, respectively. Neg-negative status; Pos-positive status;
replication selective for cancers with disrupted retinoblastoma (Rb) tumor suppressor pathway. 61 The intermediate backbone vector Ad5DE1/DE3, CMV-KISS1, F5/3 was generated by HR in bacteria between the fiber gene-modified vector Ad5DE1/DE3, F5/3 62 and an E3 shuttle vector, harboring deletion of the E3 region sequence starting from the last 44 bases of the E3A 12.5K gene CDS up to the last 18 nucleotides of the E3B 14.7K CDS. The KISS1 cassette was PCR amplified using sense and antisense primers and cloned into the unique SalI site of the above E3 shuttle downstream of the SwaI site-flanked kanamycin (Kan) gene. Following homologous recombination (HR) of the fiber-deleted backbone plasmid with the modified E3 shuttle recombinant clones were screened using 2 sequential PCR-assays detecting Ad5 pIX (or Ad5 hexon) gene-specific sequences followed by detection of the 3 0 knob sequences of the F5/3 fiber chimera. Since the E3 shuttle vector carried the wild-type fiber gene sequence as part of one of its "recombination arms" (RA), the latter assay was performed to verify that HR occurred upstream of the Ad3 knob domain sequence of the Ad5DE1/DE, KISS1, F5/3 backbone vector and the Ad3 knob sequence of the F5/3 chimera fiber gene was not replaced by the Ad5 knob sequence of the E3 shuttle. Incorporation of the Kan gene in the intermediate backbone plasmid allowed selecting recombinants on 2 antibiotics: Amp and Kan. Following HR of the Ad5DE1/DE3, CMVKiss1, F5/3 with the PmeI-linearized E1 shuttle vector pSlD24E1, pIX-mCherry and colony selection on Kan, the E1 recombinants were screened using a PCR assay. The accuracy of HR was additionally verified by restriction digest with HindIII and NheI. A mixture of 2 nonrecombined plasmids was used as a control to account for a strand switch as a possible mechanism for false-positive signal. Miniprep plasmid DNA isolated from positive BJ clones was retransformed in the stable strains STBL4 or DH5-a (Invitrogen), and following colony rescreening and plasmid upscaling, linearized with PacI and transfected into the HEK-293 helper cells with Lipofectamine 2000 (Thermo Fisher-Invitrogen, 11668027).
Generation and molecular validation of conditionally replicative adenoviruses (CRAds)
All viruses were generated and plaque-purified in E1-complementing retinoblastoma 911 cells according to standard procedures. The CRAds were propagated in A549 adenocarcinoma cells. All viruses were purified by double cesium chloride ultracentrifugation (AdEasy system; QBiogene-MP, 11AES2016) and dialyzed against phosphate-buffered saline (Fisher Scientific, 20-012-027) with 10% glycerol. Viral particle titer for the purified preparations of each virus was determined by absorbance at 260 nm as described previously. 62 The absence of contamination with the wild-type E1A sequence-containing genomes (known as RCA) in virus preparations as well as genomic identity of each virus was verified by conventional PCR assays. Incorporation of pIX-mCherry fusion protein in the viral capsids and their molecular integrity was confirmed by western blot as using mouse monoclonal ANTI-FLAG Ò M2 (Sigma-Aldrich, F3165). Antibody binding was detected using the ECL TM chemiluminescence detection system (GE Healthcare, 45-002-401). Infectious titers were determined in HEK-293 helper cells by the 50% tissue culture infectious dose (TCID50) method. The limiting dilution end point and infectious titer (TCID50/ml) were determined by the K€ arber equation: TCID50/ml D 10[1CD(S-0.5)]/V, where D is the logarithm of the dilution factor (e.g., D D 1 for the 10-fold serial dilution), S is the logarithm of the initial dilution plus the sum of ratios of infection-positive wells per total wells at each subsequent dilution, and V is the volume of the diluted vector, used for inoculation, in milliliters (ml).
Antibodies for immunoblotting, immunofluorescence and histology
The following primary antibodies were used for western blot- the above lentiviruses and 24 h later virus-containing culture media was replaced with complete media supplemented with 1.2 mg/ml of puromycin. Puromycin-resistant clones were selected by culturing transfected cells for 2 wk under selective conditions.
Cell proliferation
MTT cell proliferation assay was performed according to the manufacturer's instruction for the Cell proliferation kit I (Roche, 11465007001). Results were expressed as a ratio between treated and untreated (mock) cells multiplied by 100%. Four wells were sampled as replicates per each experimental group in a given experiment. Data values are presented as means § standard deviation.
Cell viability-calcein AM test
Cell membrane integrity was evaluated after transfection of cancer cells with siRNA, shRNA plasmids or infection with 1 multiplicity of infection of Ad or Ad-KISS1 vectors by incubation of the cells with 2 mM calcein-AM. The assay was performed in 96-well plates as recommended by the vendor with 300 ml well volume (0.32 cm 2 growth area) and 100-ml sample volume per each well.
Boyden and Invasion assays
The migration property of MDA-MB-231Br based cells lacking KISS1 (KISS1-KD61, KISS1-KD79 or shScrambled) pretreated with mock, adenovirus (Ad) or Ad-KISS1 vectors, 4T1Br-based transient transfected cells with Kiss1-KDA or shScrambled control was assessed using the Boyden assay. Briefly, 5 £ 10 4 cancer cells were seeded in the top chamber of the BD cell migration system either covered (invasion test) or not covered with Matrigel (migration test;Trevigen, 3433-001-01). As a chemoattractant DMEM media supplemented with 10% FBS, serum-free DMEM (SF medium), normal astrocyte media (ScienCell, 1801) supplemented with astrocyte growth supplement (ScienCell, 1852) or astrocyte conditioned medium (ScienCell,1811-sf) supplemented with CXCL12/SDF1 (10 mg/ml; Peprotech, 300-28A) were used. Following a 24-h incubation, the number of migrating cells per field was counted using an Zeiss Axiovert 135 inverted microscope (Thornwood, NY, USA) at 10X magnification. A minimum of 8 images were collected and processed via MetaMorph software (Olympus, Japan).
Luciferase assay
MDA-MB-231Br cells were plated at a density of 5 £ 10 4 cells per well in a 96-well plate 24 h before transfection. The next day, GoClone plasmids expressing fusion constructs of Luciferase reporter gene and the 3 0 UTR sequences containing either the MIR345 binding site, mutated MIR345 binding site or control vector were mixed (at a concentration of 30 ng/ml) with Gibco OPTI-MEM medium (Fisher Scientific, 31-985-062), MIR345 mimic (SwicthGear Genomics, MIM0334), nontargeting (SwitchGear Genomics, MIM9001), and Fugene HD reagent (Promega, E2311) as per the protocol recommended by SwitchGear Genomics (Carlsbad, CA). After 30 min of incubation, 5 ml of transfection mixture was added to the each well. Cells were incubated for the next 48 h before measuring luciferase activity using a LightSwitch Assay kit (SwitchGear Genomics, LS010).
GFP analysis of KISS1 inhibition by MIR345-mimic
For analysis of GFP activity, CN34Br cells stable expressed GFP-KISS1¡3 0 UTR fusion were plated in 24-well culture plate 24 h before treatment with NHA conditioned media alone or in combination with AMD3100, serum-free media supplemented with CCL2 or CXCL12, transfection with noncoding MIR-mimic (20 nM; GE Healthcare, CN-00100) or MIR345-mimic (MIR345-5p, 20 nM; GE Healthcare, c-300711) MIR345-mimic or nontargeting MIR mimic were delivered into target cells using DharmaFECT1 (GE Healthcare, T-2001). Activity of GFP expression was determined 48 h after transfection. From 5 to 8 GFP images were captured by phase-contrast fluorescent microscopy and signal intensity from region of interest (ROI) was assessed by ROI manager (ImageJ software).
Angiogenesis array
Semi-quantitative analysis of human cytokines was performed using a sandwich-based membrane-antibody array C1000 (AAH-ANG-1000) according to the vendor's recommendations (RayBiotech). Images were acquired with a Gel Doc XR System (Bio-Rad, Hercules, CA, USA) and analyzed relative to a positive control.
ELISA
Cells were seeded at the density of 50,000 cells per well 24 h before infection with a replication competent adenoviral vector expressing KISS1 (Ad-KISS1) or an "unarmed" control vector (Ad). After 24 h of infection an unbound virus containing media was replaced with either a complete media or a serumfree medium (ELISA test) for the next 48 h of incubation. At 72 h post infection, supernatant from cells was harvested as per the manufacturer's instructions (KISS1 Enzyme Immunoassay Kit; Phoenix Pharmaceuticals Inc., EK-048-56). Detection of human KISS1 was performed by using biotinylated rabbit anti-KISS1 antibodies (Phoenix Pharmaceuticals Inc., EK-048-56) and streptavidin-horse radish peroxidase (HRP) conjugate (Phoenix Pharmaceuticals Inc., EK-SA-HRP). Signal was detected upon addition of the substrate solution (TMB; Phoenix Pharmaceuticals Inc., EK-SS) and measuring absorbance at 450 nm wavelength as per the vendor's protocol. Four wells were sampled per each experimental group and absorbance presented as mean § standard deviation (SD).
Flow cytometry analyses
mCherry-positive CTCs were detected in the blood by flow cytometry using BD FACSAria Cell sorter (BD Biosciences, San Jose, CA). Blasticidin-resistant blood-derived MDA-MB-231 cells (CTC) were expanded and then stained with CD44, CD24 and EPCAM antibodies. 21 
Immunoblot analysis
Approximately 2 £ 10 5 cells were lysed in 1X NP40 (Calbiochem, 492018)-based extraction buffer (20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP40, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 250 mg/ml benzamide, 50 mM NaF, and 1 mM NaO 3 V 4 ) and Halt TM Protease Inhibitor Cocktail (Pierce-Thermo Scientific, 78429). Ten mg of total protein per sample was loaded onto a gel. After incubation with primary antibodies overnight, membranes were probed with either the secondary HRP goat anti-mouse antibody (Bio-Rad, 1721011), or HRP goat anti-rabbit antibodies (Bio-Rad, 1721019), and visualized with a Bio-Rad Imaging Station (BioRad). Protein expression was quantified by band densitometry analysis using a Chemidoc Touch Imaging System (BioRad, Hercules, CA, USA) and data from 2 independent experiments were plotted vs housekeeping protein controls. Data were presented as fold change in protein expression level relative to that of the corresponding protein in scrambled shRNA constructtransfected cells.
RT-PCR and quantitative RT-PCR
A) Detection of cellular mRNAs. Extraction of total RNA from treated or untreated BrCa cells and human astrocytes was performed by using an RNeasy Mini Kit (Qiagen, 74104). Reverse transcription was performed using an iScript TM cDNA Synthesis kit (Bio-Rad, 1708890). Quantitative RT-PCR analysis was performed in triplicate by using the Power SYBR R PCR Master Mix (Applied Biosystems-Thermo-Fisher Scientific, 4368577) or iQ SYBR Green Supermix (Bio-Rad, 170-8880) according to the manufacturer's instructions, in a 10-ml reaction volume. Samples were run on a Bio-Rad Opticon II PCR station (Bio-Rad, Hercules, CA, USA) or ABI 7900HT Cycler (Applied Biosystems-Life Technologies,Waltham, MA). Expression levels were normalized to that of the human Actin (ACTB) gene. Amplification specificity was verified by melting curve analysis and agarose gel electrophoresis. B) Detection of cellular miRNAs. Total RNA containing microRNA and mRNAs were extracted from formalinfixed paraffin embedded tissue using an FFPE RNA extraction Kit (Qiagen, 73504) and from adherent cells using TRIzol reagent (Thermo Fisher Scientific, 15596026) according to the manufacturer's instructions. The quality of isolated RNA was determined with an Agilent and ND1000 Nanodrop Spectrophotometer (Nanodrop Technology-Thermo Scientific, Wilmington, DE, USA) before cDNA conversion using qScript miR cDNA Synthesis (Quanta Biosciences, 95107-100). The level of selective miRNAs expression was established by using PerfeCTa SYBR Green PCR SuperMix microRNA assay (Quanta Biosciences, 95053-500), miRNA specific assay (HSMIR-0345-5P) relative to cellular RNU6-2 (HS-RNU6). The comparative DDCt method was used to calculate the relative changes in gene expression by using an OPICON 2 Real time PCR machine (Bio-Rad).
Soft agar colony formation assay: In vitro tumorigenicity analysis
A methylcellulose colony formation assay was performed as described. Briefly, soft agar assays were performed by plating suspension of 1 £ 10 4 cells in 1% low melting agarose. Cell colonies stained with 0.005% crystal violet colonies were counted 14 d later by drawing the grid on the plate. Experiments were repeated twice in triplicates.
Immunohistochemistry
Human brain or BrCa tissues were fixed overnight in 10% formalin solution (Thermo-Fisher Scientific, SF98-4). Fivemicron-thick sections were deparaffinized, rehydrated and quenched in 1% hydrogen peroxide in methanol. Antigen retrieval was performed in 10 mM sodium citrate, pH 6.0, 0.1% Tween-20 (Fisher BioReagents, BP337-500). Blocking was done in 10% normal serum (Vector Laboratories, S-5000), 1% BSA (Sigma-Aldrich, A2153), and 0.1% Tween-20, followed by incubation with the primary antibodies diluted in 1% BSA overnight at 4 C. After incubating with secondary HRP-conjugated antibody, sections were developed with DAB Peroxidase (HRP) Substrate Kit (Vector Laboratories, SK-4100). Slides were counterstained with Gill's hematoxylin-eosin (SigmaAldrich, 1051740500), and mounted with Histomount (Fisher Scientific-National Diagnostics, 50-899-90137) before examination on a Zeiss AxioImager A2 microscope (Zeiss, Thornwood, NY).
Immunofluorescence
To determine the colocalization of CD24 and CD44, CCL2 and GFAP, CXCL12 and GFAP, EPCAM with CD44 and CD24, KISS1 with CD44 and GFAP markers, we performed immunofluorescent multicolor staining. Antigen retrieval was performed in citrate buffer, pH 6.0. The blocking step was performed by incubating the slides with Background Buster (Accurate Chemical & Scientific Corporation, NB306/50) and endogenous biotin activity was quenched followed by incubation with mouse antibody, rabbit antibody, or Alexa Fluor 488-labeled rabbit antibody (Novus Bio, NB110-89474AF488). The secondary biotinylated antibody (Vector Laboratories, BA-9200) treatment was followed by Streptavidin-Alexa Fluor 594 conjugate (Life Technologies -Molecular Probes, S32356). For negative controls the treatment was exactly the same except that the primary antibody was omitted. Slides were mounted in VECTASHIELD Antifade mounting medium containing DAPI (Vector Laboratories, H1200). Protein expression in tissue sections were visualized using a Leica SP5 AOBS Laser Scanning confocal microscope (Solms, Germany) with x90 (1,3 NA) or x60 (1.45 NA) oil objectives, or confocal images of immunofluorescently stained cells grown on coverslips were acquired with an Nikon Eclipse Ti-U microscope (Tokyo, Japan) and images were captured by a Nikon digital sight DS-Qi1Mc camera, imported into and analyzed by IP Labs.
Orthotopic MDA-MB-231 BrCa model
The MDA-MB-231-mCherry model was established as described previously. 23 Fourteen, 28 and 42 d later, blood samples (1 ml) were collected from the heart, purified using GE Helathcare TM Percoll R centrifugation media (Fisher Scientific, 45-001-748) gradient centrifugation, 24 and cultured in medium containing 1 mg/ml blasticidin (Sigma-Aldrich, 203351). One wk later, Cherry-positive cells were subjected to flow cytometry using antibodies against CD24, CD44 and EPCAM markers. At 2, 4 and 6 wk post tumor implantation the number of mCherry-positive cancer cells was determined by Flow cytometry.
Statistics
All statistical analyses were performed using GraphPad Prism software. Statistical analysis of the data was performed using the Student unpaired t test, as indicated in the figure legends. A Log Rank test was using to compare the Kaplan-Meier survival curves. All experiments were performed twice and independently; P values <0.05 in all cases indicate statistical significance. 
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